Reduction of platelet cytosolic phospholipase A2 activity by atorvastatin and simvastatin: Biochemical regulatory mechanisms

Thrombosis Research

Volumn 131, Issue 4, 2013, Pages

  Moscardó, Antonio ^a   Vallés, Juana ^a   Latorre, Ana ^a   Madrid, Isabel ^a   Santos, María Teresa ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

aspirin; cPLA2; MAPKs; platelets; statins; thromboxane A2

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; ATORVASTATIN; CALCIUM; CYCLOOXYGENASE 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOLIPASE A2; PRAVASTATIN; SIMVASTATIN; THROMBOXANE A2;

ARTICLE; CELL STIMULATION; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; THROMBOCYTE; THROMBOCYTE AGGREGATION;

ANTICHOLESTEREMIC AGENTS; ASPIRIN; BLOOD PLATELETS; CALCIUM; COLLAGEN; CYCLOOXYGENASE 1; DRUG COMBINATIONS; DRUG SYNERGISM; HEPTANOIC ACIDS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHOLIPASE A2 INHIBITORS; PHOSPHOLIPASES A2; PHOSPHORYLATION; PLATELET AGGREGATION; PRAVASTATIN; PYRROLES; SIMVASTATIN; THROMBOXANE A2; THROMBOXANE-A SYNTHASE;

EID: 84875744511     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.01.007     Document Type: Article

References (37)

1. M. Briel, N. Vale, G.G. Schwartz, J.A. de Lemos, F. Colivicchi, and F.R. den Hartog Updated evidence on early statin therapy for acute coronary syndromes: Meta-analysis of 18 randomized trials involving over 14,000 patients Int J Cardiol 158 2012 93 100
2. T. Lenderink, E. Boersma, A.K. Gitt, U. Zeymer, L. Wallentin, and F. Van de Werf Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than non-users: a report from the first Euro Heart Survey on acute coronary syndromes Eur Heart J 27 2006 1799 1804
3. S.J. Lewis Lipid-lowering therapy: who can benefit? Vasc Health Risk Manag 7 2011 525 534
4. J.R. Schaefer Lipid management for the prevention of cardiovascular disease Curr Pharm Des 17 2011 852 860
5. J.K. Liao Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol Am J Cardiol 96 2005 24F 33F
6. M. Takemoto, and J.K. Liao Pleiotropic effects of 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitors Arterioscler Thromb Vasc Biol 21 2001 1712 1719
7. M. Labiós, M. Martínez, F. Gabriel, V. Guiral, E. Martínez, and J. Aznar Effect of atorvastatin upon platelet activation in hypercholesterolemia, evaluated by flow cytometry Thromb Res 115 2005 263 270
8. A. Notarbartolo, G. Davì, M. Averna, C.M. Barbagallo, A. Ganci, and C. Giammarresi Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia Arterioscler Thromb Vasc Biol 15 1995 247 251
9. K. Schrör, P. Löbel, and E. Steinhagen-Thiessen Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia Eicosanoids 2 1989 39 45
10. G. Davì, M. Averna, I. Catalano, C. Barbagallo, A. Ganci, and A. Notarbartolo Increased thromboxane biosynthesis in type IIa hypercholesterolemia Circulation 85 1992 1792 1798
11. J.W. Eikelboom, G.J. Hankey, J. Thom, D.L. Bhatt, P.G. Steg, and G. Montalescot Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk Circulation 118 2008 1705 1712
12. L. Puccetti, F. Santilli, A.L. Pasqui, S. Lattanzio, R. Liani, and F. Ciani Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia Atherosclerosis 214 2011 122 128
13. M.T. Santos, M.P. Fuset, M. Ruano, A. Moscardo, and J. Valles Effect of atorvastatin on platelet thromboxane A(2) synthesis in aspirin-treated patients with acute myocardial infarction Am J Cardiol 104 2009 1618 1623
14. A.J. Marcus, J.I. Gallin, and R. Snyderman Platelets: their role in hemostasis, thrombosis and inflammation Inflammation: Basic Principles and Clinical Correlates 1999 Lippincott Williams & Wilkins Philadelphia 77 95
15. C.C. Leslie, T.A. Gangelhoff, and M.H. Gelb Localization and function of cytosolic phospholipase A2alpha at the Golgi Biochimie 92 2011 620 626
16. A. Moscardo, J. Valles, M. Pinon, J. Aznar, V. Martinez-Sales, and M.T. Santos Regulation of cytosolic PlA2 activity by PP1/PP2A serine/threonine phosphatases in human platelets Platelets 17 2006 405 415
17. A. Moscardo, M.T. Santos, M.P. Fuset, M. Ruano, and J. Valles Residual cyclooxygenase-1 activity and epinephrine reduce the antiplatelet effect of aspirin in patients with acute myocardial infarction Thromb Haemost 105 2011 663 669
18. L. Asmis, F.C. Tanner, I. Sudano, T.F. Lüscher, and G.G. Camici DMSO inhibits human platelet activation through cyclooxygenase-1 inhibition. A novel agent for drug eluting stents? Biochem Biophys Res Commun 391 2010 1629 1633
19. M.T. Santos, A. Moscardo, J. Valles, M. Martinez, M. Pinon, and J. Aznar Participation of tyrosine phosphorylation in cytoskeletal reorganization, alpha(IIb)beta(3) integrin receptor activation, and aspirin-insensitive mechanisms of thrombin-stimulated human platelets Circulation 102 2000 1924 1930
20. C.C. Leslie Regulation of the specific release of arachidonic acid by cytosolic phospholipase A2 Prostaglandins Leukot Essent Fatty Acids 70 2004 373 376
21. H. Osamah, R. Mira, S. Sorina, K. Shlomo, and A. Michael Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets Br J Clin Pharmacol 44 1997 77 83
22. S. Matetzky, P. Fefer, B. Shenkman, M. Shechter, I. Novikov, and N. Savion Statins have an early antiplatelet effect in patients with acute myocardial infarction Platelets 22 2011 103 110
23. J. Niessen, G. Jedlitschky, M. Grube, S. Bien, H. Schwertz, and S. Ohtsuki Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin Drug Metab Dispos 37 2009 1129 1137
24. S.E. Nissen, E.M. Tuzcu, P. Schoenhagen, B.G. Brown, P. Ganz, and R.A. Vogel Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial JAMA 291 2004 1071 1080
25. C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, and R. Belder Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
26. J.R. Murrow, S. Sher, S. Ali, I. Uphoff, R. Patel, and M. Porkert The differential effect of statins on oxidative stress and endothelial function: atorvastatin versus pravastatin J Clin Lipidol 6 2012 42 49
27. M. Marzilli Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering Am J Cardiovasc Drugs 10 Suppl. 1 2010 3 9
28. T.R. Pedersen Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering Am J Cardiovasc Drugs 10 Suppl. 1 2010 10 17
29. V.G. Athyros, K. Tziomalos, M. Florentin, A. Karagiannis, and D.P. Mikhailidis Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect? Curr Med Res Opin 26 2010 839 842
30. T.C. Chou, Y.F. Lin, W.C. Wu, and K.M. Chu Enhanced nitric oxide and cyclic GMP formation plays a role in the anti-platelet activity of simvastatin Br J Pharmacol 153 2008 1281 1287
31. Y.M. Lee, W.F. Chen, D.S. Chou, T. Jayakumar, S.Y. Hou, and J.J. Lee Cyclic nucleotides and mitogen-activated protein kinases: regulation of simvastatin in platelet activation J Biomed Sci 17 2010 45
32. J.X. Song, J.Y. Ren, and H. Chen Simvastatin reduces lipoprotein- associated phospholipase A2 in lipopolysaccharide-stimulated human monocyte-derived macrophages through inhibition of the mevalonate-geranylgeranyl pyrophosphate-RhoA-p38 mitogen-activated protein kinase pathway J Cardiovasc Pharmacol 57 2011 213 222
33. J.A. Rosado, and S.O. Sage The ERK cascade, a new pathway involved in the activation of store-mediated calcium entry in human platelets Trends Cardiovasc Med 12 2002 229 234
34. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients Br Med J 324 2002 71 86
35. J. Valles, M.T. Santos, M.P. Fuset, A. Moscardo, M. Ruano, and F. Perez Partial inhibition of platelet thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with ST-segment elevation myocardial infarction Am J Cardiol 99 2007 19 25
36. A.L. Frelinger, Y. Li, M.D. Linden, M.R. Barnard, M.L. Fox, and D.J. Christie Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization Circulation 120 2009 2586 2596
37. B. Luzak, J. Rywaniak, L. Stanczyk, and C. Watala Pravastatin and simvastatin improves acetylsalicylic acid-mediated in vitro blood platelet inhibition Eur J Clin Invest 42 2012 864 872